Indoco Remedies · NSE: INDOCO · BSE: 532612
Q3 FY24 results · Oct–Dec 2023
Indoco Remedies reported revenue from operations of ₹459.42 crore (up 15.1% from Q3 FY23) and net profit of ₹15.56 crore (down 44.7% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 459.42 | 399.20 | +15.1% | 481.73 | −4.6% |
| Other income | 2.35 | 0.36 | +552.8% | 4.43 | −47.0% |
| Total income | 461.77 | 399.56 | +15.6% | 486.16 | −5.0% |
| Profit before tax | 22.63 | 38.22 | −40.8% | 46.28 | −51.1% |
| Net profit for the period | 15.56 | 28.14 | −44.7% | 35.24 | −55.8% |
| Attributable to shareholders of the company | 16.30 | 28.14 | −42.1% | 35.08 | −53.5% |
| EPS, basic (₹) | 1.69 | 3.05 | −44.6% | 3.82 | −55.8% |
| Net margin (%) | 3.4 | 7.0 | 7.3 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 449.05 | 398.64 | +12.6% | 473.39 | −5.1% |
| Other income | 2.93 | 0.37 | +691.9% | 1.12 | +161.6% |
| Total income | 451.98 | 399.01 | +13.3% | 474.51 | −4.7% |
| Profit before tax | 27.02 | 37.85 | −28.6% | 44.03 | −38.6% |
| Net profit for the period | 20.01 | 27.87 | −28.2% | 33.14 | −39.6% |
| EPS, basic (₹) | 2.17 | 3.02 | −28.1% | 3.60 | −39.7% |
| Net margin (%) | 4.5 | 7.0 | 7.0 |
Consolidated
- Filed with BSE
- 23 Jan 2024, 18:19 IST
- Board meeting
- 23 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jan 2024, 18:19 IST
- Board meeting
- 23 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE